98696-20-9

Upstream product

• 2211-94-1 2,3-epoxypropyl p-methoxyphenyl ether 
• 100-51-6 benzyl alcohol 

Downstream Products

• 213828-28-5 1-(benzyloxy)-3-(4-methoxyphenoxy)acetone 
• 249930-31-2 [5-benzyloxymethyl-5-(4-methoxy-phenoxymethyl)-tetrahydro-furan-2-yl]-acetic acid tetradecyl ester 
• 249930-16-3 Tetradecanoic acid 2-benzyloxymethyl-4-[1-methoxycarbonyl-meth-(Z)-ylidene]-tetrahydro-furan-2-ylmethyl ester 
• 249930-14-1 Tetradecanoic acid 2-benzyloxymethyl-4-[1-methoxycarbonyl-meth-(E)-ylidene]-tetrahydro-furan-2-ylmethyl ester 
• 249930-24-3 methyl (E)-7-(benzyloxy)-6-hydroxy-[(4-methoxyphenoxy)methyl]-2-heptanoate 
• 249930-25-4 [5-benzyloxymethyl-5-(4-methoxy-phenoxymethyl)-tetrahydro-furan-2-yl]-acetic acid methyl ester 
• 249930-30-1 [5-benzyloxymethyl-5-(4-methoxy-phenoxymethyl)-tetrahydro-furan-2-yl]-acetic acid 
• 249930-11-8 (Z)-methyl 2-{4-{[(4-methoxyphenyl)methoxy]methyl}-4-[(phenylmethoxy)methyl]-3-oxolanylidene}acetate 
• 249930-12-9 (E)-methyl 2-{4-{[(4-methoxyphenyl)methoxy]methyl}-4-[(phenylmethoxy)methyl]-3-oxolanylidene}acetate 
• 249930-22-1 1-(benzyloxy)-2-[(4-methoxyphenoxy)methyl]-5-hexen-2-ol 
• 249930-10-7 5-{[(4-methoxyphenyl)methoxy]methyl}-5-[(phenylmethoxy)methyl]oxolan-3-one 
• 213828-29-6 1-(benzyloxy)-2-[(4-methoxyphenoxy)methyl]-4-penten-2-ol 
• 249930-15-2 [5-Benzyloxymethyl-5-hydroxymethyl-dihydro-furan-(3Z)-ylidene]-acetic acid methyl ester 
• 249930-13-0 [5-Benzyloxymethyl-5-hydroxymethyl-dihydro-furan-(3E)-ylidene]-acetic acid methyl ester 

Relevant academic research and scientific papers

DIACYLGLYCEROL LACTONE COMPOUND, PREPARATION METHOD THEREFOR, AND IMMUNOSTIMULATOR CONTAINING SAME AS ACTIVE INGREDIENT

Disclosed are a novel diacylglycerol lactone compound for improving immunity and inhibiting infection by promoting neutrophil movement, a preparation method therefor, and an immunostimulator containing same as an active ingredient. The diacyloglycerol lactone compound is represented by chemical formula 1 of the specification. In chemical formula 1, R1 and R2 are respectively N and independently a C2-30 fatty acid group.

Protein kinase C ligands based on tetrahydrofuran templates containing a new set of phorbol ester pharmacophores

A series of substituted tetrahydrofurans with an embedded glycerol backbone carrying additional tetrahydrofuranylideneacetate or tetrahydrofuranylacetate motifs were grouped into four distinct templates (I- IV) according to stereochemistry. The compounds were designed to mimic three essential pharmacophores (C3-C=O, C20-OH and C13-C=O) of the phorbol esters according to a new, revised model. The tetrahydrofuran ring was constructed from glycidyl 4-methoxyphenyl ether, and the structures of the isomeric templates were assigned by NMR spectroscopy, including NOE. The binding affinity for protein kinase C (PKC) was assessed in terms of the ability of the ligands to displace bound [3H-20]phorbol 12,13-dibutyrate (PDBU) from a recombinant α isozyme of PKC. Geometric Z- and E-isomers (1 and 3, respectively) containing a tetrahydrofuranylideneacetate motif were the most potent ligands with identical K(i) values of 0.35 μM. Molecular modeling studies of the four templates showed that the rms values when fitted to a prototypical phorbol 12,13-diacetate ester correlated inversely with affinities in the following order: I ? II > III > IV. These compounds represent the first generation of rigid glycerol templates seeking to mimic the binding of the C13-C=O of the phorbol esters. The binding affinities of the most potent compounds are in the same range of the diacylglycerols (DAGs) despite the lack of a phorbol ester C9-OH pharmacophore surrogate. This finding confirms that mimicking the binding of the C13-C=O pharmacophore of phorbol is a useful strategy. However, since the C9-OH and C13-C=O in the phorbol esters appear to form an intramolecular hydrogen bond that functions as a combined pharmacophore, it is possible the lack of this combined motif in the target templates restricts the compounds from reaching higher binding affinities.